Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026)

Edgewise Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$595.4 million in Q1 2026.

• Quarterly Retained Earnings fell 170.16% year-over-year to -$595.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$595.4 million (down 170.16% YoY) and the FY2025 annual result came in at $1.1 billion, up 254171.67% from the prior year.
• Retained Earnings eased to -$595.4 million in Q1 2026 per EWTX's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $1.1 billion in Q4 2025 and troughed at -$595.4 million in Q1 2026.
• A 5-year average of $108.7 million and a median of -$1.1 million in 2024 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 655475.93% in 2022, down 326224.24% in 2022.
• Over 5 years, Retained Earnings stood at -$1.4 million in 2022, then surged by 107.31% to $99000.0 in 2023, then soared by 324.24% to $420000.0 in 2024, then soared by 254171.67% to $1.1 billion in 2025, then slumped by 155.75% to -$595.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$595.4 million, $1.1 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.